Page 4 - தலை ஆஃப் உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தலை ஆஃப் உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தலை ஆஃப் உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் Today - Breaking & Trending Today

Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

Published: May 10, 2021
Galafold® (migalastat) PerformanceReflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M
1Q21 Total Galafold Revenue of $66.4M Driven by Continued Global Growth
Positive Pre-BLA Meeting Held with U.S. FDA for AT-GAA in Pompe Disease; Rolling BLA Submission On-Track for Completion in 2Q21with Global Submissions Expected Throughout 2021
New Data from Pompe and Fabry Gene Therapy Programs to be Presented at American Society of Gene & Cell Therapy 24th Annual Meeting May 11th-14th
Continue to Strengthen Senior Management Team with Addition of Sébastien Martel as SVP, Strategy & Business Development ....

United States , United Kingdom , Andrew Faughnan , Diana Moore , Bradleyl Campbell , Johnf Crowley , Amicus Therapeutics , Senior Management Team , Strategy Business Development , American Society Of Gene Cell Therapy , Head Of Global Corporate Communications , Amicus Therapeutics Inc , University Of Pennsylvania Penn , Company Fabry , European Union , Performancereflects Continued Strong Adoption , All Key Global Regions , Achieve Revenue Guidance , Galafold Revenue , Continued Global , Pompe Disease , Global Submissions Expected Throughout , Fabry Gene Therapy Programs , American Society , Cell Therapy , Annual Meeting May ,

Amicus Therapeutics Appoints Sébastien Martel as Senior

Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization
PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) Amicus Therapeutics (Nasdaq: FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company’s corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team.
Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President, Global Head of Rare Diseases at Sanofi. Mr. Martel has played a key role in managing the launch and growth of several products across therapeutic areas and has had significant involvement in strategic merger and acquisition transactions and business development deals. He brings a proven track record in corporate and business development, global marketing ....

United States , Andrew Faughnan , Diana Moore , Sanofi Genzyme , Johnf Crowley , Novo Nordisk , Amicus Therapeutics , Burgundy School Of Business , University Of Angers , Business School , Head Of Global Corporate Communications , Amicus Therapeutics Inc , Merck Kga , Merck Kgaa , Business Development , Most Recently Served , Global Head , Rare Diseases , Deep Expertise , Corporate Strategy , Senior Vice President , Chief Executive Officer , Vice President , Specialty Care , Investor Relations , Global Marketing ,

Amicus Therapeutics Announces Successful Pre-BLA Meeting

Submissions to Seek Approval in both ERT Naïve and ERT Switch Pompe Patients
Completion of Rolling Biologics License Application On-Track by end of 2Q21
PHILADELPHIA, May 03, 2021 (GLOBE NEWSWIRE) Amicus Therapeutics (NASDAQ:FOLD) today announced the completion of a successful Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) for AT-GAA (cipaglucosidase alfa co-administered with miglustat), its investigational two-component therapy for the treatment of Pompe disease. Based on this formal pre-BLA meeting and the final written communication received from the FDA, Amicus intends to complete the rolling BLA submission for cipaglucosidase alfa and submit a New Drug Application for miglustat. ....

United States , Andrew Faughnan , Diana Moore , Johnf Crowley , Jeff Castelli , Amicus Therapeutics , European Medicines Agency , Drug Administration , Head Of Global Corporate Communications , Existing Data Support Regulatory , Seek Approval , Pompe Patients , Rolling Biologics License Application On Track , Typeb Pre Biologics License Application , New Drug Application , Chief Executive Officer , Chief Development Officer , Breakthrough Therapy Designation , Authorization Applications , Private Securities Litigation Reform Act , Pompe Disease , Annual Report , Global Corporate , ஒன்றுபட்டது மாநிலங்களில் , டயானா மூர் , ஜெஃப் காஸ்டெல்லி ,

Amicus Therapeutics Recognized as a Great Place to Work® in Europe

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amicus Therapeutics Recognized as a Great Place to Work® in Europe
Amicus Therapeutics, Inc.April 28, 2021 GMT
PHILADELPHIA, April 28, 2021 (GLOBE NEWSWIRE) Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been recognized by the prestigious Great Place to Work® Institute as among the best places to work in the United Kingdom, Spain, Italy and Germany. The company has also been recognized with a Best Workplaces Bavaria designation.
Great Place to Work® is an international research and consulting institute that supports organizations in developing their corporate and workplace culture. This certification indicates that an organization’s workplace culture is validated through anonymous employee feedback, based on the Grea ....

United Kingdom , United States , Andrew Faughnan , Diana Moore , David Clark , Amicus Therapeutics , Head Of Global Corporate Communications , Amicus Therapeutics Inc , Great Place , Best Workplaces Bavaria , Chief People Officer , Work For All , Investor Relations , Global Corporate Communications , Globe Newswire , Corona Virus , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , டயானா மூர் , டேவிட் கிளார்க் , அமிகஸ் சிகிச்சை , தலை ஆஃப் உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் , அமிகஸ் சிகிச்சை இன்க் , நன்று இடம் , தலைமை மக்கள் அதிகாரி , வேலை க்கு அனைத்தும் ,

GODIVA To Donate 10% Of GODIVA.com Sales To Support Cocoa Growing Communities In Celebration Of Earth Day

Share this article
Share this article
NEW YORK, April 22, 2021 /PRNewswire/ Starting this Earth Day, April 22, 2021 through the end of the month, GODIVA, the global leader in premium chocolate, will be donating 10 percent of GODIVA.com sales to Earthworm Foundation, a global non-profit that works to build a world where human, natural, and capital resources become a force for good.
Earthworm Foundation & GODIVA
GODIVA TO DONATE 10% OF GODIVA.COM SALES TO SUPPORT COCOA GROWING COMMUNITIES IN CELEBRATION OF EARTH DAY
This additional funding from GODIVA will be used to further support cocoa farming communities and cultivate forest restoration in Côte d Ivoire, the largest cocoa producing country in the world. This is part of an ongoing partnership between GODIVA and Earthworm Foundation that began last summer and strives to make long-term improvements to protect forests and enrich the lives of people who grow and harvest cocoa. One of their most recent collab ....

Bruxelles Capitale , Tara Mcteague , Mark Sanderson , Nurtac Ziyal Afridi , Pierre Draps , World Cocoa Foundation , Cocoa Forests Initiative , Earthworm Foundation , Head Of Global Corporate Communications , West Africa , Bastien Sachet , Belgian Chocolatier , Global Corporate Communications , ப்ரூக்ஸெல்ஸ் தலைநகரம் , குறி சாண்டர்சன் , உலகம் கோகோ அடித்தளம் , கோகோ காடுகள் முயற்சி , மண்புழு அடித்தளம் , தலை ஆஃப் உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் , பாஸ்டின் ஸ்யாஶே , பெல்ஜியன் சாக்லேட்டியர் , உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் ,